AllianceBernstein’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

AllianceBernstein’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,464	Closed	-$322K	–	3157
2018 Q3	$322K	Buy	+1,464	New	+$3.51M	﹤0.01%	2813
2014 Q2	–	Sell	-28	Closed	-$60K	–	3675
2014 Q1	$60K	Sell	28 -7	-20%	-$17.4K	﹤0.01%	3078
2013 Q4	$80K	Sell	35 -21	-38%	-$48K	﹤0.01%	2961
2013 Q3	$156K	Sell	56 -21	-27%	-$104K	﹤0.01%	2909
2013 Q2	$711K	Buy	+77	New	+$593K	﹤0.01%	2272

Other funds holding ONCT

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AllianceBernstein's ONCT Position: Q4 2018 in Review

AllianceBernstein sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2018, closing a stake of 1,464 shares — an estimated $322K sold.

AllianceBernstein first reported a position in ONCT in Q2 2013 and held it in 5 quarters. The position peaked at $711K in Q2 2013. 43 funds tracked by Wall St. Rank hold ONCT as of Q4 2018.

AllianceBernstein reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
AllianceBernstein sold 1,464 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $322K.
AllianceBernstein first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 5 quarters.
AllianceBernstein's Oncternal Therapeutics, Inc. Common Stock position peaked at $711K in Q2 2013.
43 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2018.

Based on AllianceBernstein's 13F filing for Q4 2018, filed 13 Feb 2019.